{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"125","value":"387"},{"groupId":"OG001","spread":"113","value":"240"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Dose Escalation 1 - Lead in Cycle Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"160","value":"361"},{"groupId":"OG001","spread":"273","value":"374"},{"groupId":"OG002","spread":"155","value":"214"},{"groupId":"OG003","spread":"210","value":"529"},{"groupId":"OG004","spread":"479","value":"829"},{"groupId":"OG005","spread":"6370","value":"4000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Induction Cycle Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"The PK parameter estimates for carfilzomib were estimated from plasma concentration-time profiles using standard noncompartmental approaches over the complete sampling interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG000","title":"Phase 1b: Dose Escalation 1 (20 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG001","title":"Phase 1b: Dose Escalation 1 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG002","title":"Phase 1b: Dose Escalation 2 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 36 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG003","title":"Phase 1b: Dose Escalation 2 (20/36 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 45 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG004","title":"Phase 1b: Dose Escalation 2 (20/45 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 56 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG005","title":"Phase 1b: Dose Escalation 2 (20/56 mg/m^2)"}],"paramType":"MEAN","populationDescription":"Phase 1b PK Analysis Set: All participants who received the study treatment regimen during the lead-in cycle and induction cycles, and had available data. Phase 1b Dose Escalation 2 arms did not have a 1-week lead-in cycle.","reportingStatus":"POSTED","timeFrame":"Lead-in Cycle Day 1 (7-day cycle) and Induction Cycle Day 8 (28-day cycle): pre-dose, 15m after the start of infusion, immediately (within 2m) before the EOI, EOI, 10m, 30m, 1h, 2 h, and 4h post-dose","title":"Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}